SanegeneBio

SanegeneBio is a private, global biotech leveraging its proprietary LEAD™ technology to develop RNAi therapies targeting obesity, cardiometabolic, and autoimmune diseases. The company has advanced multiple programs into clinical trials, supported by over $150 million in funding, and operates R&D centers in both the US and China. Its strategy centers on expanding RNAi beyond liver targets to address large patient populations with chronic conditions through tissue-specific delivery and optimized payloads.

LEAD™ (Ligand and Enhancer Assisted Delivery) technology: a proprietary platform using novel receptor-targeting ligands and pharmacokinetic enhancers to deliver optimized siRNA payloads to extrahepatic tissues (adipose, muscle, immune cells) and the liver, enabling durable gene silencing with infrequent subcutaneous dosing.

SanegeneBio competes in the RNAi space against established leaders like Alnylam (focused largely on liver targets) and newer entrants developing extrahepatic delivery. In metabolic diseases, it faces intense competition from companies developing GLP-1 agonists, dual/triple incretins, and other modalities. Its differentiation hinges on the unique tissue-targeting capabilities of its LEAD™ platform.